What's behind chronic graft versus host disease incidence curves?
Publication date: Available online 17 January 2020Source: The Lancet HaematologyAuthor(s): Alberto Mussetti, Anna Sureda (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 18, 2020 Category: Hematology Source Type: research
Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study
Publication date: Available online 13 January 2020Source: The Lancet HaematologyAuthor(s): Abi Vijenthira, Kelvin Chan, Matthew C Cheung, Anca PricaSummaryBackgroundSeveral strategies are available for the initial treatment of advanced-stage Hodgkin lymphoma, but the optimal strategy in terms of cost-effectiveness is unclear. The aim of this study was to compare the quality-adjusted effectiveness and costs of five modern treatment options for transplantation-eligible patients with newly diagnosed advanced-stage Hodgkin lymphoma.MethodsA Markov decision-analytic model was developed using a 20-year time horizon. Five of the ...
Source: The Lancet Haematology - January 15, 2020 Category: Hematology Source Type: research
Cost considerations in the first-line treatment of advanced Hodgkin lymphoma
Publication date: Available online 13 January 2020Source: The Lancet HaematologyAuthor(s): Anthony J Perissinotti (Source: The Lancet Haematology)
Source: The Lancet Haematology - January 15, 2020 Category: Hematology Source Type: research
Clinical features and outcomes of patients with Shwachman-Diamond syndrome and myelodysplastic syndrome or acute myeloid leukaemia: a multicentre, retrospective, cohort study
This study aimed to investigate the clinical features and outcomes of patients with myelodysplastic syndrome or acute myeloid leukaemia and Shwachman-Diamond syndrome, an inherited bone marrow failure disorder with high risk of developing myeloid malignancies.MethodsWe did a multicentre, retrospective, cohort study in collaboration with the North American Shwachman-Diamond Syndrome Registry. We reviewed patient medical records from 17 centres in the USA and Canada. Patients with a genetic (biallelic mutations in the SBDS gene) or clinical diagnosis (cytopenias and pancreatic dysfunction) of Shwachman-Diamond syndrome who d...
Source: The Lancet Haematology - December 24, 2019 Category: Hematology Source Type: research
Correction to Lancet Haematol 2019; 6: e398–408
Publication date: January 2020Source: The Lancet Haematology, Volume 7, Issue 1Author(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 24, 2019 Category: Hematology Source Type: research
Correction to Lancet Haematol 2019; 6: e385–86
Publication date: January 2020Source: The Lancet Haematology, Volume 7, Issue 1Author(s): (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 24, 2019 Category: Hematology Source Type: research
Bruton tyrosine-kinase inhibitor on the rise: acalabrutinib in Waldenström macroglobulinemia
Publication date: Available online 19 December 2019Source: The Lancet HaematologyAuthor(s): Christian Buske (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 21, 2019 Category: Hematology Source Type: research
Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study
This study is registered with ClinicalTrials.gov, number NCT02180724, and is ongoing, but no longer enrolling.FindingsBetween Sept 8, 2014, and Dec 24, 2015, 122 patients were assessed for eligibility, of which 106 (87%) patients were given acalabrutinib (14 were treatment naive and 92 had relapsed or refractory disease). With a median follow-up of 27·4 months (IQR 26·0–29·7), 13 (93% [95% CI 66–100]) of 14 treatment naive patients achieved an overall response and 86 (93% [86–98]) of 92 relapsed or refractory patients per both the modified 3rd and 6th IWWM criteria. Seven (50%) of 14 treatment naive patients and 2...
Source: The Lancet Haematology - December 21, 2019 Category: Hematology Source Type: research
2019 ASH Annual Meeting
Publication date: Available online 16 December 2019Source: The Lancet HaematologyAuthor(s): Farhat Yaqub (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 18, 2019 Category: Hematology Source Type: research
Alisertib plus induction chemotherapy in previously untreated patients with high-risk, acute myeloid leukaemia: a single-arm, phase 2 trial
This study is registered with Clinicaltrials.gov, number NCT02560025, and has completed enrolment.FindingsBetween Dec 31, 2015, and Aug 1, 2017, we enrolled a total of 39 eligible patients. 19 (49%) of 39 patients had secondary acute myeloid leukaemia and three (8%) had therapy-related acute myeloid leukaemia. At mid-induction, 33 (85%) of 39 patients showed marrow aplasia, six (15%) received re-induction. The median follow-up was 13·7 months (IQR 12·7–14·4). Composite remission was 64% (two-stage 95% CI 48–79), with 20 (51%) of 39 patients achieving complete remission and five (13%) achieving complete remission wit...
Source: The Lancet Haematology - December 12, 2019 Category: Hematology Source Type: research
Alisertib: a new option for acute myeloid leukaemia
Publication date: Available online 11 December 2019Source: The Lancet HaematologyAuthor(s): Xavier Thomas (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 12, 2019 Category: Hematology Source Type: research
Diagnosis, grading, and treatment recommendations for children, adolescents, and young adults with sinusoidal obstructive syndrome: an international expert position statement
Publication date: Available online 7 December 2019Source: The Lancet HaematologyAuthor(s): Kris M Mahadeo, Rajinder Bajwa, Hisham Abdel-Azim, Leslie E Lehmann, Christine Duncan, Nicole Zantek, Jennifer Vittorio, Joseph Angelo, Jennifer McArthur, Keri Schadler, Sherwin Chan, Priti Tewari, Sajad Khazal, Jeffery J Auletta, Sung Won Choi, Basirat Shoberu, Krzysztof Kalwak, Avis Harden, Partow Kebriaei, Jun-ichi AbeSummarySinusoidal obstructive syndrome, also known as hepatic veno-occlusive disease, is a potentially life-threatening complication that occurs in children undergoing haemopoietic stem-cell transplantation (HSCT). D...
Source: The Lancet Haematology - December 7, 2019 Category: Hematology Source Type: research
Proliferation and differentiation
Publication date: Available online 7 December 2019Source: The Lancet HaematologyAuthor(s): The Lancet Haematology (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 7, 2019 Category: Hematology Source Type: research
Gita Thanarajasingam: making treatment more tolerable
Publication date: Available online 5 December 2019Source: The Lancet HaematologyAuthor(s): Rachael Davies (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 6, 2019 Category: Hematology Source Type: research
Eligibility criteria in haematological cancer clinical trials—what's needed?
Publication date: Available online 5 December 2019Source: The Lancet HaematologyAuthor(s): Mattia Calissano, Maria Beatrice Panico, Daniel J O'Connor (Source: The Lancet Haematology)
Source: The Lancet Haematology - December 6, 2019 Category: Hematology Source Type: research
